Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. 2022

Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
Division of Haematology and Haemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Development of ascites is the most common form of decompensation of cirrhosis. We aimed to investigate the coagulation system in ascitic fluid and plasma of patients with cirrhosis. We determined coagulation parameters and performed clotting and fibrinolysis experiments in ascitic fluid and plasma of thoroughly characterized patients with cirrhosis and ascites (n = 25) and in plasma of patients with cirrhosis but without ascites (n = 25), matched for severity of portal hypertension. We also investigated plasma D-dimer levels in an independent cohort of patients (n = 317) with clinically significant portal hypertension (HVPG ≥ 10 mmHg), grouped according to ascites severity. Ascitic fluid was procoagulant in a clotting assay. The procoagulant potential of ascitic fluid was abolished by depletion of extracellular vesicles from ascitic fluid by filtration or by addition of a tissue factor-neutralizing antibody. Compared with plasma, extracellular vesicle-associated tissue factor activity was high in ascitic fluid, while activities of other coagulation factors were low. The extracellular vesicle-depleted fraction of ascitic fluid induced fibrinolysis, which was prevented by aprotinin, indicating the presence of plasmin in ascitic fluid. Plasma peak thrombin generation and parameters reflecting fibrinolysis were independently associated with the presence of ascites. Finally, plasma D-dimer levels were independently linked to ascites severity in our second cohort comprising 317 patients. In conclusion, coagulation and fibrinolysis become activated in ascites of patients with cirrhosis. While tissue factor-exposing extracellular vesicles in ascitic fluid seem unable to pass the peritoneal membrane, fibrinolytic enzymes get activated in ascitic fluid and may re-enter the systemic circulation and induce systemic fibrinolysis.

UI MeSH Term Description Entries
D006975 Hypertension, Portal Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN. Cruveilhier-Baumgarten Disease,Cruveilhier-Baumgarten Syndrome,Cruveilhier Baumgarten Disease,Cruveilhier Baumgarten Syndrome,Disease, Cruveilhier-Baumgarten,Portal Hypertension,Portal Hypertensions,Syndrome, Cruveilhier-Baumgarten
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
October 1970, Polski przeglad chirurgiczny,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
May 1974, East African medical journal,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
March 2013, Asian Pacific journal of allergy and immunology,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
May 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
June 1981, Digestive diseases and sciences,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
February 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
March 2000, Journal of endocrinological investigation,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
November 1989, Medizinische Klinik (Munich, Germany : 1983),
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
January 2001, Microsurgery,
Johannes Thaler, and Ton Lisman, and Peter Quehenberger, and Lena Hell, and Philipp Schwabl, and Bernhard Scheiner, and Theresa Bucsics, and Rienk Nieuwland, and Cihan Ay, and Michael Trauner, and Ingrid Pabinger, and Thomas Reiberger, and Mattias Mandorfer
December 1996, Thrombosis and haemostasis,
Copied contents to your clipboard!